Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - ibuprofenum - fahrwerk - ibuprofenum 200 mg, saccharum 2.5 g, sorbitolum liquidum non cristallisabile 500 mg, xanthani gummi, acidum citricum monohydricum, ethanolum 25.2 mg, polysorbatum 80, dinatrii edetas, aromatica (orange), natrii cyclamas, natrii benzoas 12.5 mg, aqua, ad suspensionem pro 5 ml corresp. natrium 4.6 mg. - antiphlogistisch, analgetisch, antipyretisch - synthetika

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - ibuprofenum - fahrwerk - ibuprofenum 400 mg, saccharum 5 g, sorbitolum liquidum non cristallisabile 1 g, xanthani gummi, acidum citricum monohydricum, ethanolum 50.4 mg, polysorbatum 80, dinatrii edetas, aromatica (orange), natrii cyclamas, natrii benzoas 25 mg, aqua, ad suspensionem pro 10 ml corresp. natrium 9.2 mg. - antiphlogistisch, analgetisch, antipyretisch - synthetika

Eiropas Savienība - vācu - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - impfstoffe - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. der einsatz dieses impfstoffs sollte in übereinstimmung mit den offiziellen empfehlungen.

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - paracetamolum, ibuprofenum - filmtabletten - paracetamolum 500.00 mg, ibuprofenum 150.00 mg, maydis amylum, cellulosum microcristallinum, amylum pregelificatum, carmellosum natricum conexum, magnesii stearas, talcum, pellicule: hypromellosum, lactosum monohydricum 3.81 mg, e 171, macrogolum 4000, natrii citras dihydricus, talcum, pro compresso obducto corresp. natrium max. 2.4 mg. - traitement symptomatique à court terme de la douleur légère à modérée - synthetika

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - ibuprofenum - granulat - ibuprofenum 400 mg ut ibuprofenum lysinum 683.6 mg, sorbitolum 1052.6 mg, silica colloidalis anhydrica, aromatica (verbena), aromatica (citron), aspartamum 40 mg, saccharinum natricum corresp. natrium 2.24 mg, ad granulatum, pro charta. - schmerzmittel - synthetika

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

verfora sa - ibuprofenum, pseudoephedrini hydrochloridum - kapseln - ibuprofenum 200 mg, pseudoephedrini hydrochloridum 30 mg, maydis amylum, silica colloidalis anhydrica, amylum pregelificatum, carmellosum natricum conexum, acidum stearicum, natrii laurilsulfas, matériel de la capsule: gelatina, e 171, e 131, e 127, pro capsula corresp. natrium 1.19 mg. - indiqué chez l’adolescent (15-17 ans) et l’adulte, dans le soulagement des symptômes de la congestion nasale associée à une rhinosinusite aigüe, présumée virale avec céphalée et/ou fièvre. - synthetika

Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vivanta generics s.r.o. (8174834) - injektionslösung - 20 mg/ml

Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cc-pharma gmbh (8029457) - benazeprilhydrochlorid - tablette - benazeprilhydrochlorid (23413) 20 milligramm - hund

Eiropas Savienība - vācu - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - impfstoffe - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Eiropas Savienība - vācu - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - schweine - zur aktiven immunisierung von schweinen ab einem alter von 7 wochen, um sterblichkeit zu verhindern und infektionen und krankheiten zu verringern, die durch das virus der klassischen schweinepest (csfv) verursacht werden. onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.